Cognition in Older Adults With Cancer Receiving Systemic Anti-Cancer Therapy

Condition(s) studied

Study summary

The majority of cancer diagnoses occur in adults age 65 years and over. This population is also rapidly expanding. There is a growing need for increased understanding about the potential impact of various newer therapies on common geriatric impairments in this group.

The aim of this study is to examine how feasible it is to carry out a study of cognitive function in older adults (age 65+) who are newly commencing anti-cancer treatments, specifically 'immune checkpoint inhibitor' therapy, over time. Participants in the study undergo four tests of memory and concentration every six weeks for a six month period. Additionally, the researcher will gather information about the participants' non-cancer therapy medications, physical and psychological symptoms, day to day functioning and any changes to these factors over time.

The purpose of the study is to examine a) recruitment, retention and engagement of participants to study procedures; b) to gather preliminary information about cognitive function in older adults commencing immune checkpoint inhibitor treatments and potential associations with cognitive decline over time.

Eligibility

Primary outcome measure(s)

• Recruitment — From recruitment start date (May 2024) to recruitment end date (December 2025) (18 months)
  25% of those given a Patient Information Leaflet during the recruitment period (18 months i.e. from May 2024 to December 2025) consent to the study procedures and enter the study
• Retention — 3 months from individual participant study commencement date
  50% who are still on treatment complete the 3-month assessment (primary endpoint)
• Adherence/Engagement — 3 months from individual participant study start date
  75% of cognitive tests are completed up to and including the 3-month timepoint
• Adherence/Engagement — 3 months from individual study participant start date
  75% of assessments are completed within 10 days of the 6-weekly timepoint

Trial sites (2)